Type your tag names separated by a space and hit enter




Trade Name(s)

  • Jetrea

Ther. Class.
ocular agents

Pharm. Class.


Symptomatic treatment of vitreomacular adhesion (VMA).


A proteolytic enzyme that dissolves the protein matrix present in vitreomacular adhesions.

Therapeutic Effect(s):

Dissolution of vitreomacular adhesion with improved vision.


Absorption: Minimal absorption

Distribution: Action is primarily local

Metabolism and Excretion: Rapidly degraded following administration

Half-life: Unknown.


Intravitrealwithin 1 wk3 wk6 mos or more


Contraindicated in:

  • None noted.

Use Cautiously in:

  • Lactation:Effects are not know, use caution;
  • OB: Use during pregnancy only if clearly needed;
  • Pedi: Safety and effectiveness not established.

Adverse Reactions/Side Effects

May be due to procedure

EENT: blurred vision, conjunctival hemorrhage, ↓ visual acuity, eye pain, macular hole, vitreous floaters, retinal edema, anterior chamber cell, cataract, conjunctival hyperemia, dry eye, dyschromatopsia (yellow vision), ↑ intraocular pressure, intraocular inflammation/infection, intraocular hemorrhage, iritis, lens subluxation, macular edema, metamorphopsia (distorted vision), photophobia, photopsia (perceived light flashes), retinal degeneration, retinal detachment, vitreous detachment

* CAPITALS indicate life-threatening.
Underline indicate most frequent.



None noted.


Intravitreal: (Adults) 0.125 mg injected as a single dose.


Solution for intravitreal injection: 0.375 mg/0.3 mL


  • Monitor for elevation in intraocular pressure following injection.
  • Monitor visual acuity periodically following injection; may lead to decrease in vision.

Potential Diagnoses


  • Ocriplasmin must be administered by a qualified physician.
  • Intravitreal: Remove vial from freezer and allow to thaw for few min at room temperature. Solution is clear and colorless without particles; do not administer solutions that are discolored or contain particulate matter. Withdraw all solution from vial with a 19 gauge needle. Replace needle with 30 gauge needle and expel excess air and solution to 0.1 mL. Discard unused solution. Administer adequate anesthesia and a broad spectrum antibiotic as per protocol. Intravitreal injection is done via aseptic technique. Repeat administration in same eye is not recommended.
    • Wait 7 days before treating other eye if necessary.

Patient/Family Teaching

  • Explain procedure for intravitreal injection to patient.
  • Advise patient to notify health care professional immediately if signs and symptoms of intraocular inflammation/infection (eye redness, sensitivity to light, eye pain, change in vision) occurs.
  • May cause visual changes. Advise patient to avoid driving and other activities requiring good vision until response to medication is known.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

Improved vision in patients with vitreomacular adhesions.

ocriplasmin is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Emergency Central is a collection of disease, drug, and test information including 5-Minute Emergency Medicine Consult, Davis’s Drug, McGraw-Hill Medical’s Diagnosaurus®, Pocket Guide to Diagnostic Tests, and MEDLINE Journals created for emergency medicine professionals. Learn more.


Quiring, Courtney, et al. "Ocriplasmin." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Emergency Central, emergency.unboundmedicine.com/emergency/view/Davis-Drug-Guide/110137/all/ocriplasmin.
Quiring C, Sanoski CA, Vallerand AH. Ocriplasmin. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://emergency.unboundmedicine.com/emergency/view/Davis-Drug-Guide/110137/all/ocriplasmin. Accessed April 21, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Ocriplasmin. In Davis's Drug Guide. Available from https://emergency.unboundmedicine.com/emergency/view/Davis-Drug-Guide/110137/all/ocriplasmin
Quiring C, Sanoski CA, Vallerand AH. Ocriplasmin [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 April 21]. Available from: https://emergency.unboundmedicine.com/emergency/view/Davis-Drug-Guide/110137/all/ocriplasmin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - ocriplasmin ID - 110137 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://emergency.unboundmedicine.com/emergency/view/Davis-Drug-Guide/110137/all/ocriplasmin PB - F.A. Davis Company ET - 16 DB - Emergency Central DP - Unbound Medicine ER -